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Abstract 
 
Nano-enabled lipid based drug delivery systems offer a platform to overcome 
challenges encountered with current failed leads in the treatment of parasitic and 
infectious diseases. When prepared with FDA or EMA approved excipients, they can 
be readily translated without the need for further toxicological studies, while they 
remain affordable and amenable to scale-up. Buparvaquone (BPQ), a 
hydroxynapthoquinone with in vitro activity in the nanomolar range, failed to clinically 
translate as a viable treatment for visceral leishmaniasis due to its poor oral 
bioavailability limited by its poor aqueous solubility (BCS Class II drug). Here we 
describe a self-nanoemulsifying system (SNEDDS) with high loading and thermal 
stability up to 6 months in tropical conditions able to enhance the solubilisation 
capacity of BPQ in gastrointestinal media as demonstrated by flow-through cell and 
dynamic in vitro lipolysis studies. BPQ SNEDDS demonstrated an enhanced oral 
bioavailbility compared to aqueous BPQ dispersions (probe – sonicated) resulting in 
an increased plasma AUC0-24 by 55% that is four fold higher than any previous 
reported values for BPQ formulations. BPQ SNEDDS can be adsorbed on low 
molecular glycol chitosan polymers forming solid dispersions that when compressed 
into tablets allow the complete dissolution of BPQ in gastrointestinal media. BPQ 
SNEDDS and BPQ solid SNEDDS demonstrated potent in vitro efficacy in the 
nanomolar range (<37 nM) and were able to near completely inhibit parasite replication 
in the spleen and 48 ± 48 and 56 ± 23% inhibition of the parasite replication in the liver 
respectively compared to oral miltefosine after daily administration over 10 days. The 
proposed platform technology can be used to elicit a range of cost-effective and orally 
bioavailable non-invasive formulations for a range of antiparasitic and infectious 
disease drugs that are needed for closing the global health innovation gap.  
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Introduction 
 
Advances in biotechnology and drug delivery have transformed medicine in the 
industrialised world, but these innovations have yet to reach developing countries. 
More than 10 million people in the developing countries die of infectious and parasitic 
diseases such as malaria, leishmaniasis, HIV/AIDS, tuberculosis, and diarrheal 
diseases annually, while morbidity related to these diseases devastates economic 
development 1. More importantly, the burden of infectious and parasitic illness falls 
more heavily on children and pregnant women 2.  
Many of these diseases have earned the label of “neglected”, because health-care 
markets in the affected countries are insufficient to attract pharmaceutical industry 
funding in research and development. These involve African Trypanosoniasis, Chagas 
diseases, dengue, leishmaniasis, leprosy, lymphatic filariasis, malaria, 
onchocerciasis, schistosomiasis and tuberculosis 3. Over the past decade, public-
private, not-for-profit, product development partnerships (PDPs) have arisen to tackle 
the development of new drugs, vaccines, diagnostics for developing-world diseases, 
while governments and foundations have increased their investment in neglected 
diseases research and development. The challenge remains to augment these public 
and private sector efforts by providing to those partnerships access to advanced 
technologies and expertise for discovering, delivering and developing new medicines 
4.  
Leishmaniasis presents as cutaneous, mucosal and visceral forms caused by 
protozoa of the genus Leishmania that spread in humans through the bite of a 
phlebotomine sandfly 5.  The cutaneous and mucosal forms cause severe 
disfigurement and disability resulting in gender inequality, stigmatisation and reduction 
of economic productivity 6, while the visceral (VL) form is fatal if left untreated (with a 
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100% fatality rate within 2 years). An estimated 12 million people are infected with 
Leishmania with 50,000 deaths annually 7, while 1.3 million new cases are reported 
every year putting in risk 310 million people 6 over a wider geographical distribution 
today due to urbanisation, migration and deforestation, making leishmaniasis a 
growing public health concern 8.  To complicate things further, up to twelve percent of 
all VL cases are associated with HIV/AIDS, while highest prevalence is reported in 
sub-Saharan countries (20-40% of cases) 9-11.  
First line treatment for VL relies on pentavalent antimonials [sodium stibogluconate 
(SSG) and N-methylglucamine antimoniate (meglumine antimoniate)] 12. As resistance 
to antimonials is increasing limiting their use, emerging second-line treatments involve 
pentamidine and Amphotericin B (AmB)13, 14. AmB is highly effective in VL when 
administered intravenously. Available parenteral formulations involve an affordable 
micellar formulation (Fungizone®), which is highly nephrotoxic limiting the dose able 
to be administered, and a liposomal formulation (Ambisome®) with the latter used first 
line in the developed world. Other parenteral formulations involve lipidic complexes 
(Abelcet®), but these are less likely to be used due to their higher cost compared to  
Ambisome® 13. As AmB parenteral formulations are thermally unstable, cost of therapy 
is raised further to account for the need for cold transport and refrigeration. To 
overcome this issue, the clinical use of a heated Fungizone® has been attempted in  
in India. This involved a 10-fold aqueous dilution of Fungizone® and heating to 70 oC 
for 20 minutes 15, which elicits larger AmB aggregates that are not renally cleared 
reducing observed nephrotoxicity 16. Pentamidine, on the other hand, has been shown 
to cause insulin dependent diabetes which is irreversible and potentially fatal 17. 
Miltefosine, the only oral VL licensed treatment (licensed in 2003 in India), has a long 
elimination half-life (7 days) and a narrow therapeutic index. These pharmacokinetic 
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characteristics limit the administered dose which can result in subtherapeutic levels 
over several weeks encouraging the emergence of resistance 18. Indeed, resistance 
has been reported in India (a county that alone accounts for 50% of the VL worldwide 
burden) and France 13, 19. Thus, available medicines for VL are outdated, impractical 
(non-oral, requiring hospitalisation and access to healthcare professionals over long 
treatment periods), insufficiently efficacious, or subject to resistance and unacceptable 
toxicities 4, 20-22. Based on this, an ideal treatment for VL would possess greater than 
95% efficacy, be orally administered, be stable in a tropical environment, be affordable 
and require less than 11 days treatment with an excellent side-effect profile 23.  
Buparvaquone (BPQ), a hydroxynapthoquinone licensed for theileriosis as an 
intramuscular injection, possesses promising activity in the nanomolar range against 
Leishmania spp. amastigotes (ED50: 0.005μM against L. donovani) 24. Although in vitro 
experiments have provided promising results in the 90s, in vivo activity up to oral doses 
of 100 mg kg-1 has been low, due to its poor solubility in physiological fluids (<300 ng 
mL-1, Log D: 7.02 at pH 3.0) and low oral bioavailability 24, 25, which hindered its 
translation into a viable therapy. Attempts to improve BPQ’s aqueous solubility and 
bioavailability have included the generation of water soluble BPQ phosphate prodrugs 
26-28, the use of nebulised nanosuspensions 29 BPQ nanosuspensions in 
mucoadhesive hydrogels 30, oral suspensions and cyclodextrin complexes with limited 
success31. The most promising results towards an oral bioavailable BPQ formulations 
involved the use of self-emulsifying drug delivery system (SEDDS) 25. However, the 
oral efficacy of the BPQ SEDDS have not been demonstrated. Here we present, a 
novel BPQ loaded self-nanoemulsifying drug delivery system (BPQ-SNEDDS) with 
potent in vitro and in vivo activity along with oral pharmacokinetic and 
pharmacodynamic studies. Additionally, we present a facile easily scalable method to 
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convert these BPQ-SNEDDS into solid nanomedicines for the treatment of VL. The 
proposed formulations are cost-effective, thermally stable and prepared from generally 
regarded as safe excipients (GRAS) that can enable their facile clinical translation, 
while they can be used for other poorly antiparasitic and chemotherapeutic drugs for 
the treatment of parasitic and infectious diseases. 
 
Methods 
 
Materials 
Buparvaquone (>95% HPLC) was obtained from Toronto Research Chemicals 
(Toronto, Canada). Capryol 90 (propylene glycol monocaprylate 90%), Labrasol 
(Labrasol ALF, Caprylocaproyl macragol-8 glycerides), Labrafil M 1944 CS 
(Oleoylocapryoyl macragol-6 glycerides) were kindly provided by Gattefosse 
(Berkshire, UK) and soya phosphatidylcholine (Lipoid S100) by Lipoid GmbH (Rein, 
Germany). Pancreatin (porcine, P1625, ≥ 3 USP), bile extract (porcine) and all other 
chemicals, solvents, and acids, unless otherwise stated, were of ACS grade or above 
and were obtained from Sigma-Aldrich (Dorset, UK) and used without further 
purification. Cell culture media were bought from Sigma-Aldrich (Madrid, Spain).  
Preparation of BPQ loaded SNEDDS (BPQ SNEDDS) 
BPQ loaded SNEDDS (BPQ SNEDDS) were prepared by combining BPQ, Labrafil 
1944CS (oleoyl macragol-6 glycerides), Capryol 90 (propylene glycol monocaprylate) 
and Labrasol (caprylocaproyl macragol-8 glycerides) (0.01:3:1:5.99 w/w) under stirring 
at 600 rpm. This ratio was identified using pseudo-ternary phase diagram studies 
constructed with varying concentrations of oily solubilisers (Labrafil M 1944 CS) and 
oil soluble surfactants (Labrasol) and co-surfactants (Capryol 90) and double-distilled 
water using the water titration method at room temperature25 (Figure SI-1). The 
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samples were placed into a water bath at 37 ± 0.5°C for 24 hours under gentle shaking 
(Kotterman D1365, Hänigsen, Germany). Mixtures were then observed for turbidity 
when fresh and at 24 hours and particle size was measured when fresh and after 24 
hours as described below. Turbidity is indicative of the formation of a coarse emulsion, 
whereas a clear isotropic solution would indicate a microemulsion (type II).  
All formulations containing BPQ were protected from light. BPQ SNEDDS (10, 20 and 
50 mg mL-1) were prepared in triplicate as described above to determine the maximum 
BPQ loading within the SNEDDS. After 24h, the samples were taken out from the 
waterbath and centrifuged at 10,000 rpm for 10 minutes (Jouan B4i centrifuge, Thermo 
Scientific, USA) and the supernatant was isolated and analysed using HPLC (after a 
1 in 250 dilution with methanol) as described below.  
Photon Correlation Spectroscopy (particle size & zeta potential measurements)  
SNEDDS were diluted with water at 1 in 200 v/v and 1 in 100 v/v (pH 6.5) prior to 
particle size and zeta-potential measurements respectively (Malvern Zetasizer Nano-
Zs, Malvern Instruments, Worcestershire, UK) at 25 oC and at a wavelength of 633 
nm. The data were analysed using the Contin method of data analysis. Diluted 
suspensions were left for 15 minutes at room temperature (25°C) before particle size 
was measured. The accuracy of the instrument was assessed periodically using a drop 
of latex beads (polystyrene, mean size: 0.1 µm) in 50 mM sodium chloride (dispersed 
phase). All measurements (n=13) were performed in triplicate and the mean (±SD) 
was reported. 
Zeta potential (Malvern Nano-Zs, Malvern Instruments, UK) was measured for the 
diluted formulations utilizing the Doppler electrophoresis technique. Analysis of the 
Doppler shift (Fourier transformed) was done by using a mixed-mode measurement 
phase analysis light scattering (M3-Pals). The viscosity of the sample was 
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hypothesized to be the viscosity of water at 25oC. All measurements (n=100) were 
performed in triplicate and the mean (±SD) was reported. 
HPLC analysis  
A modified reverse phase HPLC (RP-HPLC-UV) method based on the optimized and 
validated method published by Venkatesh et al 32 was used. A Phenomenex Onyx 
Monolithic C18 column (10+100mm x 4.6mm, 5 µm) was maintained at 30°C (Varian 
Prostar column heater) for analysis and the analytical wavelength was set to 251 nm 
and 342 nm (Varian Prostar, Agilent technologies Inc, USA). The mobile phase 
consisted of 1% acetic acid in water, acetonitrile and methanol in the ratio 30:60:10 
(v/v/v) and was filtered (Millipore nylon filter 0.45 µm) and degassed using bath 
sonication (175W, Jencons scientific Ltd, Bedfordshire, UK). The injection volume was 
set at 40 µL per sample using Varian Prostar autosampler (model 410, Agilent 
technologies Inc, USA) and a flow rate of 1.5 mL min-1 was achieved using a Varian 
Prostar solvent delivery module (Agilent technologies Inc, USA) . The retention time 
was 5.54 minutes for BPQ and the lowest detection limit was set at 0.05 µg mL-1. A 
linear calibration curve in a range of 0.05 to 100 µg mL-1 was used for extrapolation of 
the concentrations.  
Flow-through cell dissolution studies for BPQ SNEDDS  
The dissolution of BPQ from BPQ-SNEDDs (10 mg mL-1, 0.3mL) loaded capsules (NP 
CapsTM, pullulan, size 2, Capsugel) was studied in the flow through cell (USP, 
Apparatus IV) at various pH levels [USP 2013 simulated gastric fluid without enzyme 
(1.2), acetate buffer (4.5) and phosphate buffer (6.8), flow rate 6 ml min-1] as previously 
described 14. 
In vitro lipolysis 
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In vitro lipolysis experiments were performed as previously described 33. The lipolysis 
medium contained bile salts (5 mM) and phosphatidylcholine (1 mM) which simulate 
fasted conditions in the gastrointestinal tract (GIT), while the digestion buffer (300 mL) 
was composed of sodium chloride (150 mM) and Trizma maleate (2 mM) at pH 6.5 ± 
0.05 33.  A low buffer concentration was chosen to ensure that ionized fatty acids are 
able to change pH, while a buffer with low capacity was selected to allow the released 
fatty acids (FA) to reduce the pH and thus trigger the addition of sodium hydroxide 33. 
The lipase suspension was prepared by suspending pancreatin (16.6 g) in 110 mL of 
Millipore water at 37oC and thoroughly mixing prior centrifugation (4,000 rpm, 7 
minutes at 37oC). The pH of the supernatant was adjusted to 6.5 using 1 M sodium 
hydroxide and 100 mL was used to initiate the lipolysis. To avoid denaturation, 
preparation of the pancreatin suspension never exceeded 15 minutes. For the in vitro 
digestion study, the lipolysis medium (300 mL) were pre-warmed at 37°C, prior to the 
addition of BPQ loaded SNEDDS (3g) and adjusting the pH to 6.5 ± 0.01 with 1 M 
sodium hydroxide. Lipolysis was initiated by adding the 100 mL of the freshly prepared 
lipase suspension. Ca2+ solution (0.5 M) was added at a dispensing rate of 0.045 mM 
(90 µL) per min (NE-1000 Programmable single syringe pumps, World Precision 
Instruments Ltd., Hertfordshire, UK). Throughout the study, the pH was kept constant 
at 6.5 ± 0.01 (Accumet AB200 equipped with an accuTupH rugged bulb, Fisher 
Scientific, Loughborough, UK) by addition of 1 M sodium hydroxide. In this respect, 
the number of OH- ions present in the volume of the titrant can be equated with the FA 
liberation caused by lipolysis. Samples (30 mL) were withdrawn at time 0, 5, 15, 30, 
60, and 90 minutes after the addition of the lipase suspension. Samples were frozen 
using dry ice prior ultracentrifugation at 40,000 rpm at 4oC (CP100NX, Hitachi Koki 
Co. Ltd, Milton Keynes, UK). The amount of BPQ present in the supernatant and in 
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the pellet was quantified after their appropriate dilution with methanol using HPLC as 
described above.  
Stability studies of BPQ SNEDDS 
Blank SNEDDS and BPQ SNEDDS (10mg mL-1, 0.5 mL, n=3) were divided into amber 
HPLC vials and stored  under 75% relative humidity in amber dessicant jars containing 
a saturated sodium chloride solution (20 g of sodium chloride in 10 mL of de-ionised 
water) at 40oC (Raven Incubator, LTE Scientific, Oldham, UK). Samples (10 μL) were 
diluted with water (1 in 200 v/v, pH 6.5) and analysed for particle size and zeta-
potential, while samples (10 μg)  were diluted with methanol and analysed by HPLC 
as described above at weeks 0, 2, 3, 4, 6, 10, 12, 16, 20, 24. Morphology of the diluted 
aqueous dispersions of the stability samples was assessed by transmission electron 
microscopy at week 0 and week 6 as described below.  
Preparation of BPQ loaded solid SNEDDS (BPQ solid SNEDDS) 
Low molecular weight glycol chitosan polymers were produced from 2 g of glycol 
chitosan that were added to freshly prepared 4M hydrochloric acid (152 mL), and 
stirred (500 rpm, IKA Werke RTC basic, IKA laboratories, Staufen, Germany) until 
homogenous (25 min) as previously described 34. The solution was then placed in a 
50°C waterbath under vigorous shaking (50 rpm) for a total of 24 hours (Kotterman 
D1365, Hänigsen, Germany). The polymer solution was dialysed with six changes (5 
L) of de-ionised water over 24 hours (Dialysis membrane Molecular weight cut-off for 
Cytochrome C: 12-14 kDa, Medicell Ltd, London, UK). The recovered degraded glycol 
chitosan (GC 14 kDa) was snap-frozen using liquid nitrogen and lyophilised (Edwards 
Modulyo freeze drier [Crawley, UK] connected to CIT Alcatel vacuum pump [Pfeiffer, 
Asslar, Germany]) over 72 hours at -50oC.  
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Blank SNEDDS (3mL) and BPQ SNEDDS (3mL, 10 mg mL-1) were adsorbed onto 400 
mg of degraded glycol chitosan (14 kDa).  Croscarmellose sodium (295 mg) was 
added followed by the addition of lactose BP (5.2 g, BP: British Pharmacopoeia) and 
mixed in a mortar and pestle.  The contents of the mortar were transferred into a round-
bottom flask and 60-70mls of de-ionised water were added and stirred until a 
homogenous viscous yellow suspension was prepared. The resulting suspension was 
snap-frozen with liquid nitrogen and lyophilised (Edwards Modulyo freeze drier 
[Crawley, UK] connected to CIT Alcatel vacuum pump [Pfeiffer, Asslar, Germany]) 
over 24 hours at -50oC. The resulting lyophilised product (15mg) was diluted with 15 
mL methanol, vortexed for 1 minute (Topmix vortex, Fischer Scientific, Leicestershire, 
UK), and centrifuged at 10,000 rpm (Jouan B4i centrifuge, Thermo Scientific, USA) for 
10 minutes before the supernatant was analysed using HPLC for drug loading as 
described below. The solid powders were also characterised using DSC, TGA, PXRD, 
FT-IR, SEM, and particle size as described below. Physical mixtures of lyophilised 
BPQ and blank solid SNEDDS (1:10 and 1:100 w/w) were also analysed via DSC and 
PXRD. 
Morphological characterisation 
A drop of the diluted SNEDDS or Solid SNEDDS (1 in 200 v/v or 1 in 200 w/v) was 
placed on Formvar©/Carbon Coated Grid (F196/100 3.05 mm, Mesh 300, Tab Labs 
Ltd, England) and stained with 1% aqueous Uranyl Acetate before TEM analysis as 
previously described (FEI CM120 BioTwin Transmission Electron Microscope) 35. 
Dry powders left to air dry was mounted on a glass slide that was mounted on a 
standard SEM sample holder and fixed on a brass/aluminium stub using double sided 
carbon impregnated adhesive discs. The sample was then sputtered coated with a 
conducting gold-palladium (10 nm, 60% gold-palladium) coating using a SEM coating 
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system for 2 minutes at 30 mA (Quorum Q 15ORES, Quorum technologies Ltd, Lewes, 
UK, Deposition range: 0-80 mA, Deposition rate: 0- 25 nm min-1, Sputter timer: 0-60 
min, Vacuum Pump: 50 L min-1, room temperature) before being viewed and 
photographed under a range of magnifications under high vacuum using JEOL JSM-
6060LV  (Jeol, Welwyn Garden City, UK) scanning electron microscope.  
Powder X-Ray Diffraction (PXRD) 
PXRD analysis was performed with a Rigaku MiniflexII desktop X-ray diffractometer 
(Rigaku, Tokyo, Japan) attached to a Haskris cooling unit (Grove Village, IL, USA). 
The PXRD patterns were recorded from 5° to 40° on the 2 theta at a step scan rate of 
0.05° per second as previously described (n=3)36. X-ray powder patterns of single 
crystal structures were calculated using Mercury® (version 3.9., Cambridge 
Crystallographic Data Centre, Cambridge, UK) and Miller's indices of various facets of 
the crystal were identified (SI-3)37. Mercury® was also used to predict the Bravais, 
Friedel, Donnay and Harker (BFDH) morphology to provide an insight into the 
molecular arrangement of different crystal facets of BPQ crystals (SI-3) 37.  
Thermal analysis  
Differential Scanning Calorimetry (DSC) experiments were performed using a Mettler 
Toledo DSC 821e (Greifensee, Switzerland) with a refrigerated cooling system 
(LabPlant RP-100, Filey, UK) as previously described 36 with nitrogen as the purge 
gas. Aluminum sample holders (40 μL) were sealed with a lid and pierced to provide 
three vent holes. Sample weight (3-6 mg) was sufficient to provide proper contact 
between the powder and the bottom of the pan. DSC measurements were carried out 
at a heating/cooling rate of 10°C min-1. The unit was calibrated with indium standards. 
The DSC system was controlled by Mettler Toledo STARe software (version 6.10) 
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working on a Windows NT operating system. Temperatures of melting and 
crystallisation events refer to onset temperatures. Details for thermogravimetric 
analysis (TGA) is provided in supplementary information (SI-4).  
Fourier-Transformed Infra-red (FT-IR) spectroscopy 
The infrared absorption spectra were obtained using a PerkinElmer Spectrum 1 FTIR 
Spectrometer (PerkinElmer, Massachusetts, USA) equipped with a Universal 
Attenuated Total Reflectance (UATR) accessory and a diamond/zinc selenide (4000 
to 650 cm-1) crystal accessory 36. Baseline correction and data normalization were 
performed using Spekwin32 version 1.71.6.1 (maximum resolution is 1 cm-1).  
Hausner ratio and compressibility index of BPQ solid SNEDDS 
BPQ solid SNEDDS (1 g) was placed in a 5 mL measuring cylinder and the volume 
was recorded. Tapped density was calculated by tapping cylinder into a hard surface 
10, 20, 40, 60, 80, 100, 120, and 150 times, recording the volume after each set of 
taps. The Hausner ratio and compressibility index were determined as described by 
the equations below: 
𝐶𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦 𝐼𝑛𝑑𝑒𝑥 = 100 
V𝑜−V𝑓
V𝑜
                                                           (Equation 1) 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑅𝑎𝑡𝑖𝑜 =  
V𝑜
V𝑓
                                                                                   (Equation 2) 
where Vo is the unsettled apparent volume and Vf is the final tapped volume.  
Preparation and characterisation of BPQ solid SNEDDS tablets 
Lyophilised BPQ solid SNEDDs (300 mg) or blank solid SNEDDS (300 mg) were 
compressed for 10 seconds under 1 bar of pressure using a flat-faced 12mm die 
(Specac manually operated hydraulic press, Analytical accessories Ltd, Kent, UK).  
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Disintegration was tested as specified in the British Pharmacopoeia 2018 38. Tablets 
were placed in a basket rack assembly, and raised/lowered 30 times per minute at a 
distance of 55 ± 2 mm in 1L of water heated to 37.0 ± 0.5°C (Erweka disintegration 
tester ZT500 series, Erweka GmBH, Heusenstamm, Germany).  
Friability studies were conducted using 10 BPQ solid SNEDDS tablets (300 mg) 
according to British Pharmacopoeia 2018 method for uncoated tablets. Friability was 
expressed as the percentage of weight loss that was calculated by weighing the tablets 
after 100 rotations of the drum in 4 min. Tablets were dusted and accurately weighted. 
Six BPQ solid SNEDDS tablets (300 mg) were crushed using a mortar and pestle and 
the powder was extracted with 50 mL of methanol, filtered using Whatman No 1 filter 
paper and the filtrate was made up to 100 mL with methanol in a volumetric flask. The 
concentration in the final solution was measured using HPLC as described above to 
identify the uniformity of content. The dissolution of six BPQ solid SNEDDS tablets 
(300 mg) were tested using the basket method (Appendix I, BP 2018) using a GB 
Caleva Ltd Ascott model 657 dissolution apparatus, with a Tecam TE7 Tempette 
heating system. Tablets were immersed in 500 mL of pH 1.2 ± 0.1  for the first hour, 
after which 400 mL of pH 6.8 buffer were added and the final pH was adjusted to 6.8 
using 5 M sodium hydroxide (between 4 - 4.5 mL). The first media was prepared by 
mixing sodium chloride (2 M, 250 mL) and hydrochloric acid (2 M, 425 mL) and making 
them up to 1L with deionised water (pH 1.2). The second media contained 250 mL 
potassium dihydrogen phosphate (2 M, 250 mL) and sodium hydroxide (2 M, 112 mL) 
that were made up to 1L with deionised water (pH 6.8). Samples (5 mL) were removed 
at 2, 4, 8, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 105, 120, 145, 150, 165 and 180 
minutes and replaced with appropriate volume of the required buffer. Samples were 
then diluted 1:1 with methanol, vortexed for 30 seconds (Topmix vortex, Fischer 
16 
 
Scientific, Leicestershire, UK), centrifuged at 10,000 rpm for 10 minutes (Jouan B4i 
centrifuge, Thermo Scientific, USA) before BPQ concentration was quantified by 
HPLC. 
In vitro leishmanicidal assays 
L. Infantum (MCAN/ES/92/BCN83) obtained from an asymptomatic dog from the 
Priorat region (Catalonia, Spain) were kindly donated by Prof Montserrat Portus 
(Universidad de Barcelona)39. Promastigotes were cultured in Schneider's Insect 
Medium at 26 °C supplemented with 20% heat-inactivated foetal bovine serum (FBS) 
and 100 U mL-1 of penicillin plus 100 μg mL-1 of streptomycin 39.  
Promastigote drug susceptibility was determined by using the sensitive fluorimetric 
resazurin model (Sigma-Aldrich®) as previously described by our group 40. Briefly, 
cultured log phase promastigotes (2.5 x105 parasites per well) were plated in 96-well 
flat-bottomed microtiter plates (200 μL/well final volume), in the presence of different 
concentrations of the studied drug or formulations. Finally, the relative fluorescence 
units (Excitation: 535 nm, Emission: 590 nm) was measured (Infinite 200, Tecan i-
Control, Männedorf, Switzerland) to determine the growth inhibition rate and then the 
IC50 calculated by Probit analysis and the statistic parameters were computed using 
SPSS Statistics v17.0 Software. 
Amastigote assays were performed using a fluorimetric assay based on resazurin 
validated by our group 41. Macrophages were plated (5 x 104 cells/well cultured in 
RPMI medium) in a microtiter plates with a flat bottom. Macrophages were then 
infected with 5 x 105 promastigotes. Plates were incubated at 33oC for 1 day and then 
at 37oC for another day. After incubation, the culture medium was removed and 
washed with buffered RPMI-HEPES (pH 7.2) to eliminate any non-internalised 
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parasites, after which tempered media RPMI (100μL) was added to each well along 
with another 100 μL of media containing different concentration of drugs or 
formulations were added. Stock solutions for Miltefosine and BPQ (20 mg mL-1) were 
prepared initially in DMSO and then diluted to 40 μg mL-1 with RPMI-HEPES media 
(pH 6.7), while blank or BPQ SNEDDS and blank or BPQ solid SNEDDS were diluted 
with  RPMI-HEPES media (pH 6.7) at a final concentration of 40 μg mL-1. Further 
dilutions of the formulations using the same media were performed and were added 
up to a final volume of 200 µL resulting in a final concentration of 40, 20, 10, 1, 0.1, 
0.01, 0.001, 0.0001, 0.00001 μg mL-1 per well. The final solvent (DMSO) 
concentrations never exceeded 0.5% (v/v) warranting no effect on parasites 
proliferation or morphology 41. Sixteen wells were used as positive untreated control 
and eight wells as negative uninfected control were adjusted also to a final volume of 
200 μL with fresh RPMI media and incubated at 37 oC for 48 hours. The culture 
medium at different drug concentrations was removed by centrifugation at 3,500 rpm 
for 5 minutes (Eppendorf 5403 Centrifuge, Eppendorf Iberica, Madrid, Spain) and 
replaced with lysis solution (0.02% sodium dodecyl sulphate in RPMI-HEPES buffer). 
After 20 minutes, the lysis solution was removed by centrifugation (3,500 rpm, 5 
minutes, 4oC). The supernatants were replaced by fresh Schneider’s culture media 
(200μL). The plates were then incubated at 26oC for another 3 days to allow the 
transformation of viable amastigotes into promastigotes and their proliferation. Finally, 
resazurin salt (2.5mM, 20μL/well) were added followed by a 3 hour incubation at room 
temperature and relative fluorescence units were measured as described below. All in 
vitro experiments were carried out for three times and by triplicate. The IC50 was 
calculated by Probit analysis and the statistic parameters were computed using SPSS 
Statistics v17.0 Software. 
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Cytotoxicity studies on murine macrophages 
J774 murine macrophages were grown in RPMI 1640 medium supplemented with 10% 
heat-inactivated FBS (30 min at 56 °C), penicillin G (100 U mL-1) and streptomycin 
(100 μg mL-1) as previously described by our group 40,53. Cells in the pre-confluence 
phase were harvested with 0.03% EDTA-0.05% Trypsin in PBS for 20 minutes and 
maintained at 37 °C in a humidified environment with 5% CO2 (Hucoa-Erlöss, Forma 
Scientific, Ohio, USA). Cytotoxicity studies were conducted using a resazurin assay 
as described previously 42 by determining the reduction of resazurin by measuring the 
Relative Fluorescence Units (RFU, 535 nm excitation wavelength and 590 nm 
emission wavelength, Infinite 200, Tecan i-Control, Männedorf, Switzerland) as in the 
promastigotes assay. Growth inhibition (%) was calculated using Equation 3: 
Growth inhibition (%) = 100 −
RFU treated wells – RFU signal to noise
RFU untreated – RFU signal to noise
 𝑥 100          (Equation 3) 
Every concentration was assayed three times and controls (medium and drug) were 
used in each test as blanks and the background was subtracted. Cytotoxicity of the 
tested drugs/formulations was defined as the 50% reduction of cell viability of treated 
culture cells with respect to untreated cells (CC50). The selectivity index (SI) was 
calculated as expressed in Equation 4 42: 
SI=  
𝐶𝐶50
𝐼𝐶50
                                     (Equation 4) 
 
In vivo pharmacokinetic studies of oral BPQ SNEDDS 
All experiments were approved and performed in accordance with the local ethics 
committee rules (Complutense University of Madrid Institutional Animal Care and 
Ethics Committee, Madrid, Spain). Male CD-1 outbred mice (6 weeks old) were 
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purchased from Harlan Iberica S.A. (Barcelona, Spain) and were housed in groups of 
5 in plastic cages in controlled laboratory conditions with ambient temperature and 
humidity maintained at ∼22 °C and 60% respectively with a 12 h light and dark cycle 
(lights on at 07:00 and off at 19:00). Food and water were available ad libitum and the 
animals acclimatized for 5–7 days prior to experiments, within the animal house.  
CD-1 mice were randomly split into groups (n = 3), fasted overnight and dosed with 
BPQ aqueous suspensions prepared by probe sonication (50% output, 200 watt for 
10 minutes) (11 mg mL–1) or BPQ SNEDDS (11 mg mL–1) at a BPQ dose of 6 mg kg–
1 were administered (as liquid suspensions via oral gavage). Mice were sacrificed at 
different time points (1, 2, 4, 7, and 24 h), and blood was harvested. Plasma was 
separated by centrifugation (2000 rpm, 15 min, 4 °C, Hermle Z323 K centrifuge, VWR, 
Poole, U.K.), and all tissues were stored at −50 °C until analyses could be performed 
on them.  
Plasma samples (100 μL) were extracted three times with acetonitrile (100 μL). After 
every extraction the mixture was vortexed (Fisher TopMix Vortex Mixer FB15024, 
Leicestershire, England) for 5 minutes and the samples were then centrifuged (8,000 
rpm for 10 minutes) (SciSpin Micro Centrifuge, Shropshire, England). The 
supernatants were pooled and evaporated to dryness in a concentrator (Savant 
Integrated SpeedVac System ISS110, Fisher Scientific, Loughborough, UK). 
Extracted plasma calibration curves were constructed by spiking (5 μL) of BPQ stocks 
in DMSO in CD-1 blank plasma to produce a range of 0.1-50 μg mL-1 and were 
extracted and dried in a similar manner to in vivo plasma samples. Extracted standards 
and samples were reconstituted with mobile phase (100 μL) and were analysed in the 
HPLC as described above.  
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Efficacy in a systemic murine model of Visceral Leishmaniasis 
All experiments were approved and performed in accordance with local ethics 
committee rules (Complutense University of Madrid Institutional Animal Care and 
Ethics Committee, Madrid, Spain). BALB/c male mice (20–25 g, 6-7 weeks) were 
purchased form Harlan Iberica S.A. (Barcelona, Spain) and were housed in groups of 
5 in plastic cages under controlled laboratory conditions with ambient temperature and 
humidity maintained at ∼22 °C and 60% respectively with a 12 h light and dark cycle 
(lights on at 07:00 and off at 19:00). Food and water were available ad libitum and the 
animals acclimatized for 5–7 days prior to experiments, within the animal house.  
The preparation of the parasites and the experimental infection were performed as 
previously described14. Each BALB/c mouse was infected with 107 promastigotes by 
intracardiac route using a syringe with 26 G needle. 
Mice were randomly split into groups (n = 8). Treatment was started on day 21 post-
infection. A negative control (distilled water) and positive control (miltefosine in distilled 
water 12mg kg-1)43, 44 were dosed by oral gavage once daily for 10 consecutive days. 
Oral BPQ SNEDDS and BPQ Solid SNEDDS (6 mg kg-1) groups were also dosed once 
daily for 10 consecutive days by oral gavage. Formulations were dosed as liquid 
suspensions of SNEDDS or solid SNEDDS (powders prior being compressed into 
tablets) via oral gavage. The final group received a BPQ in DMSO intramuscular dose 
(25 mg kg-1, 50μL) in the hind leg at day 21 and 26. Animals were killed on day 35 
post- infection. Spleen and liver from each animal were aseptically removed and 
weighted to quantify the parasite burdens. The parasite burden was quantified by the 
limit dilution assay as previously described14 and the percentage suppression of 
parasite replication (PS) was calculated using the following equation  
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𝑃𝑆 = 100 
(PC−PT)
PC
                (Equation 5) 
where PC is the number of parasites in the control group per tissue weight (g) and PT 
is the number of parasites after treatment per tissue weight (g) 45.  
Statistical Analysis 
Microsoft Office Excel 2015 was used to analyse all data and graphs were plotted 
using Microcal Origin 6.0 or GraphPad Prism 7.0. Student t-test or one-way analysis 
of variance (ANOVA) with Tukey’s post-hoc test were performed at a 5% level of 
significance using IBM SPSS Statistics 21. 
 
Results 
 
The optimal microemulsion region was achieved for SNEDDS prepared with BPQ: 
Labrafil C1944CS: Labrasol: Capryol 90 of 0.01:3:1:5.99 w/w. Drug loading studies 
with exceeding BPQ amounts (10 mg g-1, 20 mg g-1 and 50 mg g-1) demonstrated that 
the maximum loading was 16.7 ± 2.7 mg g-1, which is comparable to previous 
published reports of high loading for BPQ (Figure 1A) 25. Dispersions of BPQ SNEDDS 
illustrated a quasispherical particle size well below 300 nm (206 ± 15 nm) with low 
polydispersity (0.316 ± 0.014) and colloidal stability (-19.2 ± 0.6 mV) (Figure 1B-E). 
BPQ content, ζ-potential and particle size remained unaltered over 6 months stored at 
40 ± 2oC and 75 ± 5% RH (One Way Anova, p<0.05) (Figure SI-2, 1F).  
 
Near complete release (89.3±1.9%) was observed in flow-through cell studies (BP 
Apparatus IV) with BPQ SNEDDs filled immediate release pullulan capsules within 30 
minutes (pH1.2) (Figure 2A). BPQ remained solubilised and available for absorption 
within all different pH media tested and complete release was achieved.  
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The in vitro dynamic lipid digestion model offers information regarding drug partitioning 
during hydrolysis of triacylglycerides and quantifying the amount of solubilised drug in 
the intestinal fluids. Lipolysis was initiated by the addition of the lipase suspension 
after which the lipolytic process was monitored as a function of time. Calcium chloride 
solution was added continuously to control the accumulation of fatty acids in the 
medium by forming insoluble calcium FA soaps, which precipitate thus removing FA 
from the system and preventing accumulation33, 46. At 30 minutes, 70% of BPQ 
remained solubilised and un-precipitated, and thus available for absorption, while 
more than 10% (10.4+/-1.25%) was available for absorption even after 90 minutes, 
which is almost double previous reports available in literature for orally bioavailable 
self-emulsifying drug delivery systems (Figure 2B) 47.  
Solid SNEDDS were prepared by adsorption of BPQ loaded SNEDDS on low 
molecular glycol chitosan polymers that were suspended in water and lyophilised to 
yield BPQ loaded solid SNEDDS. (BPQ solid SNEDDS). PXRD studies illustrated that 
BPQ exhibits Bragg peaks characteristic of crystalline material even after lyophilisation 
(Figure 3A, 3B) that are characterised by a strong endothermic peak at 183oC 
corresponding to the melting point of the drug in DSC studies (Figure 4A-a, 4A-b). 
BPQ’s PXRD spectra is similar to previous reported values 48 but the difference in 
Bragg peak intensities is indicative of narrower BPQ plate crystals [Plane 001 (2θo: 
6.55) and 002 (2θo: 12.95), Figure 3 and SI-3]. Attempts to amorphise BPQ by melt 
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Figure 1. BPQ SNEDDS characteristics; A: Drug Entrapment Studies, B-D: Particle 
size, polydispersity and zeta-potential of blank and BPQ SNEDDS (n=3) respectively, 
E-F: TEM of BPQ SNEDDS (1:200 v/v aqueous dilutions) fresh and after 6 weeks 
storage at 40oC and 75% relative humidity (Bar: 500 and 100 nm respectively).  
 
quenching technique (heating up to 200oC and fast cooling by immersion in liquid 
nitrogen) was not successful with characteristic BPQ Bragg peaks diminished in 
intensity but not abolished (Figure 3C).  BPQ solid SNEDDS resulted in fewer Bragg 
peaks which were broader and of lower intensity which are related to other excipients 
(such as lactose and croscarmellose sodium) (Figure 3D-H). The absence of the 
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Figure 2. A. Cumulative BPQ release from BPQ SNEDDs pullulan capsules in flow-
through cell studies (Simulated Gastric Fluid (SGF) pH 1.2: 0-30min, Acetate Buffer 
(AB) pH 4.5: 30-60 min, Phosphate Buffer (PB) pH 6.8: 60-80 min) (n=3), B: In vitro 
lipolysis of BPQ – SNEDDs with red, green and blue bars illustrating the % of BPQ 
recovered in the oil phase, aqueous supernatant and pellet respectively (n=3).  C-D: 
TEM images of BPQ solid SNEDDs aqueous dispersions (1mg mL-1, Bar: 100nm and 
500 nm respectively). E: SEM images of BPQ solid SNEDDS (Magnification: 500x, 
5.00 KV, Bar 20 μm).  
 
characteristic peaks of BPQ (2θo: 6.55 and 12.95) points towards the amorphisation 
of BPQ (Figure 3H). Additionally, DSC analysis of BPQ solid SNEDDS illustrated no 
peak at 183oC, BPQ’s characteristic melting endotherm, suggesting also complete 
amorphisation of BPQ (Figure 4A, Table SI-1). This is further supported by studies of 
physical mixtures of lyophilised BPQ and blank SNEDDS adsorbed on low molecular 
weight glycol chitosan (1:10 w/w), which indicated a peak at 183oC and the 
characteristic BPQ Bragg peaks of crystalline BPQ (Figure 3I, 3J and 4H).  
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Figure 3. PXRD analysis of prepared blank and BPQ solid SNEDDS along with 
physical mixtures of BPQ with blank solid SNEDDS; BPQ (a), BPQ lyophilised (b), 
BPQ amorphised (c), Lactose (d), Croscarmellose Sodium (e), Glycol chitosan (14 – 
24 kDa) (f), Blank solid SNEDDS (g), BPQ solid SNEDDS (h), Physical mixture of 
crystalline BPQ with blank solid SNEDDS (1:10 w/w) (i), Physical mixture of crystalline 
BPQ with blank solid SNEDDS (1:100 w/w) (j).  
 
FT-IR analysis illustrated that BPQ exhibits two characteristics peaks, a sharp peak at 
3300 cm-1 attributed to intramolecular hydrogen bonds between the hydroxyl group of 
BPQ and a peak at 1694cm-1 belonging to the quinine carbonyl group (aromatic group 
with 2 double bonded oxygens) (Figure 4B). Physical mixtures of BPQ and blank 
SNEDDS adsorbed on low molecular weight glycol chitosan shows a peak at 1639cm-
1 indicative of crystalline BPQ. However, the absence of these peaks for BPQ solid 
SNEDDS points towards the formation of a solid dispersion (Figure 4B), due to 
hydrogen bonding between hydroxyl groups of glycol chitosan with the quinine 
carbonyl groups of BPQ and can further explain the enhanced oral bioavailability of 
BPQ 26, 27.  
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Figure 4. A;DSC thermographs of BPQ (a), BPQ lyophilised (b), Lactose (c), 
Croscarmellose sodium (d), Glycol chitosan (GC 14-24kDa) (e), BPQ solid SNEDDs 
(f), Blank solid SNEDDS (g), Physical mixtrure of BPQ (10% w/w) and blank solid 
SNEDDS (h). B; FT-IR spectra of BPQ (a), Labrasol (b), Labrafil 1944 CS (c), Capryol 
90 (d), Lactose  (e), Glycol chitosan (GC 14-24 kDa) (f), BPQ solid SNEDDS (GC 14-
24kDa) (g), Physical mixture of BPQ 10% w/w and blank solid SNEDDS (GC14) (h). 
Vertical dotted line is drawn at 1639 cm-1.  
 
Adsorption of SNEDDs onto low molecular weight glycol chitosan (GC) polymers 
resulted in the formation of porous solids. (Figure 2E). Glycol chitosan is a 
biocompatible carbohydrate polymer with good solubility in both acidic and neutral pH. 
Apart from being known to act as a mucoadhesive and oral bioavailability enhancer35, 
49, 50, chitosans can be used as a disintegrant through swelling and formation of a 
hydrogel with increasing water content and decreasing hydrogel content from the core 
to the surface 51. Formation of a porous matrix aids disintegration and can speed up 
the dissolution process. Upon reconstitution of the pre-tabletting lyophilised BPQ 
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SNEDDS adsorbed on glycol chitosan mix (BPQ solid SNEDDS), a nanosuspension 
was formed with a particle size similar to the original BPQ SNEDDS in terms of size, 
polydispersity and zeta potential (284 ± 4.6 nm, 0.372 ± 0.006, -28.5 ± 0.611 mV). 
Thus, release of SNEDDS is possible after adsorption on solid carriers (Figure 2C, 
2D).   
BPQ SNEDDS adsorbed on low molecular weight glycol chitosan and croscarmellose 
sodium resulted in a pre-tabletting mix with passable flow characteristics (Hausner 
ratio and the compressibility index was calculated to be 1.34 ± 0.03 and 25.2 ± 1.52% 
respectively)52. Friability tests of BPQ solid SNEDDS tablets demonstrated losses of 
0.89 ± 0.03 %, which are not greater than 1.0 per cent and are acceptable according 
to BP standards. BPQ solid SNEDDS tablets illustrated a uniformity of content of 87.6 
± 3.6 % which is on the lower end of BP limits (85-115%) with none of the six tested 
tablets being below 75%. Compressed tablets (275 ± 10.79 mg, 1 bar, 10 sec) were 
able to disintegrate completely in less than 8 minutes. Premixing the croscarmellose 
sodium with the glycol chitosan prior to adsorbing the drug loaded SNEDDS is critical 
in passing pharmacopoeia disintegration tests as simply adding it in the end resulted 
in times longer than 15 minutes. Additionally, the molecular weight of the carrier 
polymer (glycol chitosan) is important; using high molecular weight glycol chitosan 
polymers (~150 kDa) resulted in disintegration times well above 15 minutes 
irrespectively of the inclusion of a superdisintegrant and in the formation of viscous 
gels on the surface of the tablets that did not allow water penetration within the core 
of the tablet and the release of the SNEDDS from the solid carrier posing as a diffusion 
barrier (data not shown). Dissolution studies illustrated that 47.6 ± 14.7% BPQ was 
released within 60 minutes in simulated gastric fluids in the absence of pepsin (SGF) 
and complete release was achieved within 30 minutes after the pH was raised to 6.8 
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(Figure 5). Thus, the complete release of BPQ from solid dosage forms of BPQ 
nanomedicines and avoiding its precipitation in the absorptive part of the 
gastrointestinal tract are likely indicators of enhance oral bioavailability of BCS Class 
II drugs such as BPQ.  
 
Figure 5. Dissolution of BPQ solid SNEDDS tablets in simulated gastrointestinal tract 
fluids (SGF: simulated gastric fluid with no pepsin, and SIF: simulated intestinal fluid 
with no pancreatin).  
 
BPQ SNEDDS and BPQ solid SNEDDS showed potent in vitro efficacy in the 
nanomolar range against L Infantum amastigotes similar to BPQ in DMSO (IC50 for all 
<37 nM), while having negligible cytoxocity against murine macrophages (Table 1). 
The activity of the blank SNEDDS can be attributed to inclusion of Labrasol. We have 
recently reported that Labrasol (a mixed ester of capric and caprylic acid) possesses 
high antileishmanial activity in the micromolar range with acceptable cytotoxicity 
against murine macrophages 53. Labrafil  on the other hand did not illustrate activity 
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against Leishmania parasites similarly to low molecular weight glycol chitosan 
polymers 53.  Both BPQ and  BPQ SNEDDS illustrated a high selectivity index that are 
well above DNDi (Drug for Neglected Diseases initiative) accepted hit selection levels 
(<10 μM, SI>10)54.  
Table 1. In vitro activity in L. Infantum amastigotes 
Drug/Formulation L. Infantum 
Promastigotes 
(IC50 μg mL-1) 
SI L. Infantum   
Amastigotes 
(IC50 μg mL-1) 
SI J774             
CC50 (μg 
mL-1) 
Buparvaquone (in 
DMSO) 
<0.012 >2000 <0.005 5000 >25 
Miltefosine (in 
DMSO) 
7.19 ± 0.6 7.7 23.7 ± 1.78 2.3 55.4 ± 
4.19 
Blank SNEDDS 1.26 ± 0.10 14.2 9.5 ± 1.9 1.9 18.18 
±1.04 
BPQ SNEDDS 3.3 ± 0.09 7.6 0.093 ± 0.053 268.8 >25 
BPQ Solid 
SNEDDS  
<0.012 NS <0.005 NS NS 
Key; J774: murine macrophages, NS: Not studied, SI: selectivity index (CC50/IC50) 
 
Based on this encouraging in vitro results, we decided to conduct an in vivo 
pharmacokinetic study in healthy mice and efficacy studies in L. infantum infected 
mice. There are only a few published reports regarding the efficacy or the 
pharmacokinetic studies of BPQ administered orally. Early reports conducted in a 
BALB/c mouse model illustrated that oral treatment of BPQ formulated in 0.25% 
Cellacol (Methylcellulose) at a dose of 100 mg/kg/day over five days resulted in 43% 
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suppression of liver amastigotes 24, while treatment of infected beagles with (5mg kg-
1 day-1 for 5 days intramuscularly (IM)) failed to halt the progression of the disease55. 
Pharmacokinetic parameters after oral administration have only been published in a 
recent study conducted in rabbits that received orally a dose of 3.0 mg kg-1 of BPQ 
entrapped in SMEDDS prepared from Capryol 90: Cremophor El: Labrasol 
9.82:70.72:17.68 w/w) (Cmax: 102 ng ml-1, Tmax: 3.17 hours, t1/2: 26.44 hours, AUC 
0-60h: 2.43 μg h ml-1) 25. We decided to utilise a dose of 6mg kg-1 for a single dose oral 
pharmacokinetic studies in mice and to utilise this dose over 10 days for our efficacy 
studies according to the DNDi Target Product Profile for Visceral Leishmaniasis 23. 
BPQ SNEDDS resulted in AUC0-24h of 10.12 μg h ml-1  and a Cmax of 0.639 μg mL-1  
which are at least four fold higher than previous published reports for self-emulsifying 
systems25, while also significantly enhancing the bioavailability of BPQ compared to 
probe sonicated aqueous dispersions of BPQ after oral administration (55% increase 
in plasma AUC0-24) (Figure 6). The latter is difficult to compare as the oral bioavaibility 
of BPQ alone has not been previously published. Additionally, BPQ SNEDDS 
illustrated an enhanced half-life compared to BPQ probe sonicated aqueous 
suspensions (46.374 versus 14.415 hours). In a systemic murine model of visceral 
leishmaniasis, BPQ SNEDDS and BPQ solid SNEDDS (orally, 6 mg kg-1 over 10 daily 
doses) and BPQ in DMSO (IM, 25 mg kg-1, one dose on day 1 of treatment and one 
dose at day 5 of treatment) showed comparable efficacy to miltefosine (orally, 12 mg 
kg-1 over 10 daily doses) in inhibiting parasite replication in the spleen at a dose that 
is shown to be effective in mice 43 (Figure 7, SI-7). However, BPQ formulations were 
more variable in inhibiting parasite replication in the liver.  
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Figure 6. Buparvaquone (BPQ) plasma concentration after oral administration of BPQ 
(aqueous suspension – probe sonicated, black squares) and BPQ SNEDDS (red 
circles) formulations (11 mg g-1) to CD-1 mice (n=3). Student t-test: * p<0.05; Dose: 6 
mg kg-1 of BPQ.  
 
Figure 7. Inhibition of parasite replication after administration of oral miltefosine (12 
mg kg-1 day-1, oral, 10 doses), BPQ intramuscularly (25 mg kg-1, IM, 2 doses) and oral 
BPQ SNEDDS and BPQ solid SNEDDS (6 mg kg-1 day-1, oral, 10 doses) to BALB/c 
mice (n=6-8). Parasite burden in liver and spleen is described in SI-7.  
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Discussion 
 
Napthoquinones and its derivatives such as BPQ are widely distributed in nature and 
are known for their antibacterial, antifungal, antiviral, antitumour and antiparasitic 
effects 56. Napthoquinones interact with biological targets by forming covalent bonds 
or via their ability to undergo reversible oxidation-reduction reactions by generation of 
ROS (reactive oxygen species) by the redox cycle under aerobic conditions, by the 
inhibition of electron transport. The electron transport chain (ETC) entails the 
sequential transfer of electrons via multiprotein complexes (complex I to IV) present in 
the inner mitochondrial membrane with electron transfer between several complexes 
being mediated by ubiquinone 57. Compounds that are analogs of ubiquinone that can 
act as competitive inhibitors of cytochrome bc1 by complexing to the Qi ubiquinone 
binding site (one of two ubiquinone binding sites on cytochrome bc1 and the one that 
is oriented toward the luminal side of the inner mitochondrial membrane, as distinct 
from the Qo site, which is oriented toward the external surface of that membrane) 57. 
Studies on promastigotes and amastigotes of several species of Leishmania indicated 
that ETC is critical for the survival of these pathogens as application of antimycin A, 
an inhibitor of cytochrome bc1, or cyanide, an inhibitor of complex IV, resulted in death 
of promastigotes or amastigotes57-59. BPQ has been recently shown to be a potent 
inhibitor of cytochrome bc1 activity and the ETC, ATP production and intracellular 
amastigote growth at nanomolar concentrations24, 57.  
The activity of BPQ against Leishmania donovani was first reported in 1992 24 while 
BPQ has antiprotozoal activity against a number of parasite including Theileria parva, 
Leishmania spp., Trypanosoma cruzi, Trypanosoma brucei, Plasmodium falciparum, 
Eimeria tenella60. BPQ is currently used only in veterinary medicine as antitheilerial to 
treat East Coast fever in cattle in Eastern and Southern Africa (Butalex ©) formulated 
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as an IM injection in DMSO (2.5 mg kg-1) 60. BPQ is characterised by a long plasma 
half-life of at least 7 days and an oral LD50 greater than 8g kg-1 in rats 60 and efficacy 
against L. Donovani amastigotes in the nanomolar range (ED50: 0.005 μM) 24. The 
methylene group linking the cyclohexyl moiety to the quinone nucleus is particularly 
important for antileishmanial activity as is the presence of a lipophilic subtituent at the 
4’-position of the cyclohexyl ring 24.  In vivo BPQ is efficacious against L.donovani in a 
BALB/c mouse model and following 100 mg kg-1 for 5 days after oral administration 
resulted in 43.4% suppression of liver amastigotes (BPQ suspended in 0.25% 
cellacol). The disappointing in vivo data, when compared to in vitro potency was 
attributed to low plasma levels in the experimental animals partly due to the limited 
solubility of BPQ (<30 ng/mL over a pH range of 3.0-7.4) and high lipophilicity 26. 
Permeability studies using in-situ perfused rat intestine classified BPQ as highly 
permeable with apparent permeability value (Papp) of 0.912×10−4 cm sec-1 compared 
to propranolol which is a high permeability marker with Papp value of 0.716×10−4 cm 
sec-1 61, 62. Thus BPQ permeability is limited mostly by its aqueous solubility and 
precipitation in the gastrointestinal tracts typical of BCS Class II drugs and strategies 
to improve its dissolution are likely to have a positive effect in increasing its oral 
bioavailability.  
Although several strategies have been developed to increase BPQ’s bioavailbility,  
only self-emulsifying drug delivery systems (SEDDS) have shown some promise 
towards orally BPQ formulations 25. Lipid-based nano-enabled delivery systems are 
receiving increasingly interest in the delivery of poorly soluble antiparasitic drugs 
because they possess no or limited biotoxicity, they are able to enhance the 
solubilisation capacity of the poorly soluble in the gastrointestinal fluids (due to their 
small size and large surface area to mass ratio) and are able to enhance transcellular 
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and lymphatic oral absorption 47. Liposomal formulations are naturally taken up by 
macrophages via phagocytosis potentially delivering the antiparasitic drugs to their 
target site. However, liposomes are usually poorly loaded and are unstable in the 
gastrointestinal tract. SEDDS are able to overcome these problems by ensuring high 
drug loading and stability in gastrointestinal media, enhancing drug dissolution and 
increase the rate and extent of absorption, whilst they are easily scalable and 
amenable to low cost industrial manufacture. Excipients used in SEDDS are usually 
GRAS without the need for further toxicology to be converted from a colloidal into a 
solid dosage form via melt granulation, lyophilisation, spray-drying, physical 
adsorption onto solid carriers or simply by being filled into capsules 63. Here we 
presented a lipid-based formulation of BPQ that possesses good loading, stability at 
tropical temperatures and simulated gastrointestinal media, ability to release BPQ 
avoiding precipitation in the aqueous environment of the GIT, enhanced oral 
bioavailability while being efficacious in reducing parasite load in the spleen similar to 
miltefosine (only orally VL licensed drug) and near 50% inhibition of liver parasite load 
in murine models after 10 days or oral administration. Adsorption of this lipid based 
formulation on solid carriers and lyophilisation resulted in a solid-dosage form that can 
be readily translatable with immediate release and enhanced dissolution in the GIT.  
BPQ SNEDDS were isotropic mixtures of Labrasol: Capryol 90 and Labrafil 1944CS 
that yield a stable nanoemulsions upon dilution in aqueous media with a particle size 
well below 300 nm of quasispherical shape and good colloidal stability (Figure 1). 
These excipients were selected based on their HLB values to ensure the production 
of a clear microemulsion type II but also the solubility of BPQ in them (Labrasol: 17 ± 
0.28, Labrafil: 12.39 ± 0.35, Capryol 90: 15.58 ± 0.57 at 37oC) 25. Additionally, we have 
recently shown that Labrasol, a mixed ester of capric and caprylic acid, was shown to 
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possess high antileishmanial activity in the nanomolar range 53. Inclusion of non-ionic 
surfactants such as Labrafil 1944CS has also been shown to enable their diffusion 
through mucous layers 64.  
The near complete release of BPQ from BPQ SNEDDS loaded in pullulan capsules in 
flow-through cell studies (USP Apparatus IV) supports that BPQ remains solubilised 
and available for absorption within all different pH media tested (Figure 2A). The in 
vitro lipolysis model was used to simulate the in vivo digestion process of lipid-based 
formulations of BPQ. The pH was maintained at 6.5 to simulate the fasted conditions 
of the intestine 65 and to ensure the activity of pancreatic lipase 66. Lipid digestion was 
started by the addition of the lipase enzyme while the liberation of free FA that causes 
a drop in pH was counteracted by addition of sodium hydroxide. As a dynamic lipolysis 
model was used, the continuous addition of calcium chloride solution controlled the 
accumulation of FA on the surface of the emulsions particles by forming insoluble 
calcium FA soaps, which precipitate and are removed from the system 33. Although 
lipid glycerides with medium chain fatty acids are subjected to faster lipolysis 47, 70% 
of BPQ remained solubilised avoiding precipitation in the GI tract available for 
absorption after 30 minutes and more than 10% was available for absorption even 
after 90 minutes which is double previous published reports for orally bioavailable 
SEDDS (Figure 2B) 47. This is important to note, as our nanoemulsions were well 
below 300 nm and it is known that reducing the size of the emulsion increases the 
specific surface area of the lipids and thus the action of pancreatic lipases 67. The 
presence of BPQ as an oil layer for 30 minutes can allow BPQ to be absorbed at a 
later stage enhancing the gastric residence time 68.  
The Target Product (treatment) Profile (TPP) for VL is based around the development 
of a safe, effective, oral, short-course (11 days maximum) VL drug formulations to 
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replace current treatments. Ideally a solid dosage form with enhanced stability in 
tropical temperatures is likely to be more cost-effective. BPQ-SNEDDS illustrated 
stability up to 6 months in tropical conditions (40oC, 75% relative humidity) in terms of 
drug content, particle size, colloidal stability and morphology (Figure SI-2). In an 
attempt to reduce the cost of a liquid filled capsule, we adsorbed BPQ SNEDDS on 
solid carriers to produce conventional solid dosage forms such as tablets. Aqueous 
dispersions of BPQ solid SNEDDS resulted in nanoemulsions of similar size and 
morphology (Figure 2C, 2D). Although the flow properties of BPQ solid SNEDDS could 
be improved by the addition of a glidant or use of micronized lactose, tablets were 
produced that passed pharmacopoeia disintegration and dissolution tests for 
immediate release tablets. Dissolution studies illustrated a pH mechanism of release 
with an initial burst release of BPQ from tablets in SGF that remained constant over 
60 minutes that was followed by a complete release of the drug when the pH was 
raised to 6.8 (Figure 6). Low molecular weight glycol chitosan polymers are 
biocompatible carbohydrate polymers with good solubility in both acidic and neutral 
pH69, 70. Chitosans are known to swell when exposed to aqueous media and the 
inclusion of a super-disintegrant enables the formation of pores to allow water 
penetration within the polymer gel structure. However, superdisintegrants are known 
to behave differently in acidic and neutral media 71. Croscarmellose sodium (Ac-Di-Sol 
©) has been shown to promote faster dissolution in neutral media than acidic 72 which 
can explain dissolution behaviour observed and favouring of BPQ release in simulated 
intestinal media. 
Solid state characterisation of BPQ solid SNEDDS is critical to understand the 
interaction of BPQ with the solid carriers at the molecular level and assess whether 
the formation of a BPQ solid dispersion or BPQ amorphisation was possible. 
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Lyophilisation of BPQ in a method used for the production of solid SNEDDS did not 
result in amorphous BPQ (Figure 3b, 4b). Similarly, attempts to amorphise BPQ by 
melt quenching which has been previously reported as a method to amorphise BCS 
Class II drugs were unsuccessful (Figure 3c). This can be explained as PXRD analysis 
indicated a prominent Bragg peak at 6.55 2θo which correlates with a hydrophobic 
surface formed by aromatic rings of BPQ (Plane 001) (Figure SI-3). Additionally, the 
intensity of the Bragg peak at 12.95 2θo corresponding to plane 002 (location of 
carbonyl groups) was also high, which indicates that h-bonding is likely to occur 
between the drug and surrounding hydrogen group donors such as glycol chitosan.  
PXRD, DSC and FT-IR studies indicate the formation of an amorphous BPQ solid 
dispersion (a product formed by the conversion of a fluid drug-carrier combination to 
the solid state 73) which is important towards improved oral bioavailability. FT-IR 
analysis also pointed to the formation of hydrogen bonding between the hydroxyl 
groups of glycol chitosan polymer chains and the quinine carbonyl group of BPQ as 
indicated by the abolishment of the 1639 cm-1 peak within the BPQ solid SNEDDS 
powders.  
Entrapment of BPQ within SNEDDS or solid SNEDDS did not affect its in vitro efficacy 
as BPQ SNEDDS and BPQ solid SNEDDS showed potent in vitro efficacy in the 
nanomolar range against L Infantum amastigotes similar to BPQ in DMSO (IC50 for all 
<37 nM) (Table 1). Both BPQ and  BPQ SNEDDS showed excellent selectivity for 
parasite versus mammalian cells with a high selectivity index that are well above DNDi 
(Drug for Neglected Diseases initiative) accepted hit selection levels 54 and that of  
miltefosine. The high selectivity of BPQ is expected as there is a high degree of 
sequence divergence between the Leishmania and human cytochrome b proteins 57.  
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In vivo pharmacokinetic studies demonstrated an earlier onset of action for BPQ 
SNEDDS compared to BPQ which supports the immediate release and enhanced 
solubilisation of BPQ in gastrointestinal media resulting in AUC0-24 that are four fold 
previous reported values for BPQ SNEDDS after a single oral administration 25.  
Although BPQ SNEDDS and BPQ solid SNEDDS were as efficacious as miltefosine 
in inhibiting parasite replication in the spleen, they were not able to control parasite 
replication in the liver. Interestingly, oral BPQ SNEDDS and BPQ solid SNEDDS (6 
mg kg-1, 10 oral doses over 10 days) were as efficacious as intramuscular doses of 
BPQ (25mg kg-1, one dose at day 1 and one dose at day 5), indicating that the reasons 
resulting in limited inhibition of parasite growth in the liver was not related to the oral 
bioavaibility of BPQ and amount of BPQ reaching the liver, but possibly due to 
metabolism of BPQ in the liver. BPQ has been reported to be metabolised by mouse 
and rat liver microsomes into an inactive red-coloured metabolic product with a half-
life of less than 10 minutes being a substrate for CYP2C9 (half-life 6 minutes) and 
CYPC19 half-life (4 minutes), while it was also metabolised by CYP3A4 (half-life 50 
minutes) 28, 74, 75. To overcome this issue and ensure orally bioavailable and efficacious 
BPQ formulations, further studies of combinations of BPQ with fluconazole, a potent 
CYP2C9, CYPC19 and CYP3A4 inhibitor shown to be efficacious in the treatment of 
visceral leishmaniasis 76, 77 can be prepared and formulated easily with described  
SNEDDS platform technology into patient compliant solid dosage forms (SNEDDS 
filled capsules or tablets). Additionally, preparing SNEDDS with a lower amount of 
long-chain triglycerides (i.e. Labrafil 1944CS ~30%w/w of final formulation) and a 
higher short and medium-chain triglycerides (e.g. Capryol 90 and Labrasol) can 
potentially decrease the accumulation of the formulation in the liver to reduce BPQ 
metabolism.  
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Conclusions 
 
Nanotechnology-enabled drug delivery systems offer a tool for overcoming the 
challenges encountered with current drugs, failed leads such as BPQ and antigens by 
improving their efficacy (and thus duration of treatment), safety, bioavailability, half-
life, while also by enabling controlled release over tailored period of times and specific 
site-targeted delivery of therapeutics. When made with FDA or EMA approved 
scalable excipients they can result in medicine that can be taken readily to phase III 
human studies providing therapeutic solutions to neglected tropical diseases. Our 
proposed nano-enabled platform technology prepared from GRAS excipients is cost-
effective while it possesses excellent loading, stability up to 6 months in tropical 
conditions, in vitro efficacy in the nanomolar range maintaining the solubilisation 
capacity of BPQ in gastrointestinal media and ensuring high oral bioavailbility for BPQ 
able to inhibit parasite replication in the spleen and in the liver. Proposed BPQ 
SNEDDS and solid SNEDDS are cost-effective, patient compliant and readily 
translated platform technologies towards a nano-enabled safe and efficacious 
treatment for parasitic and infectious diseases.    
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